idarubicin has been researched along with Carcinoma, Hepatocellular in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 16 (69.57) | 24.3611 |
| 2020's | 7 (30.43) | 2.80 |
| Authors | Studies |
|---|---|
| Bourcier, B; Lagarce, F; Lebreton, V | 1 |
| Fan, W; Li, F; Li, J; Qiao, L; Tang, Y; Wang, H; Wu, Y; Xue, M; Yue, S; Zheng, X; Zhu, B; Zou, X | 1 |
| Ahlström, H; Creusen, AD; Dahlgren, D; Ebeling Barbier, C; Hedeland, M; Heindryckx, F; Johnson, U; Khaled, J; Kullenberg, F; Lennernäs, H; Nyman, R; Nyman, SS; Rorsman, F; Sheikhi, R; Simonsson, USH; Sjögren, E; Wanders, A | 1 |
| Han, X; Huang, J; Kang, J; Kong, J; Kong, X; Li, X; Liu, H; Ma, M; Shao, G; Song, J; Sun, G; Tang, W; Xiong, F; Zhao, Y; Zheng, Z | 1 |
| Huang, M; Li, M; Wang, H; Xiang, Z; Yan, H; Zhao, C | 1 |
| Abousalihac, M; Decaens, T; Ghelfi, J; Roth, GS; Seigneurin, A; Sengel, C; Teyssier, Y | 1 |
| Bonnetain, F; Boulin, M; Cassinotto, C; Cercueil, JP; Guiu, B; Jouve, JL; Latournerie, M; Lepage, C; Loffroy, R; Minello, A; Piron, L; Schmitt, A; Wendremaire, M | 1 |
| Boulin, M; Cassinotto, C; Delicque, J; Guiu, B; Piron, L; Schwanz, H | 1 |
| Assenat, E; Barbare, JC; Barbier, E; Boulin, M; Bouvier, A; Chevallier, O; Chevallier, P; Dumortier, J; Gugenheim, J; Guiu, B; Latournerie, M; Merle, P; Nguyen-Khac, E; Oberti, F; Rode, A; Valette, PJ; Yzet, T | 1 |
| Padia, SA | 1 |
| Boulin, M; Gehin, S; Guiu, B; Pistre, P | 1 |
| Adam, H; Aho, LS; Bedenne, L; Boulin, M; Cercueil, JP; Di Martino, C; Fagnoni, P; Guiu, B; Hillon, P; Jouve, JL; Lepage, C; Minello, A | 1 |
| Bardou, M; Bedenne, L; Bonnetain, F; Boulin, M; Cercueil, JP; Chauffert, B; Dabakuyo, S; Denys, A; Grandvuillemin, A; Guerard, P; Guiu, B; Hillon, P; Jouve, JL; Lepage, C; Minello, A; Wendremaire, M | 1 |
| Lee, GH; Lim, SG | 1 |
| Bedenne, L; Boulin, M; Guiu, B | 1 |
| Blümmel, J; Boulin, M; Denys, A; Fohlen, A; Guiu, B; Pohl, T; Reinhardt, S; Schmitt, A; Wendremaire, M | 1 |
| Aho, LS; Boulin, M; Fagnoni, P; Guignard, MH; Guiu, B; Hillon, P; Lepage, C; Musat, A; Vadot, L; Vourc'h, M | 1 |
| Abergel, A; Aho, S; Boulin, M; Boyer, L; Chabrot, P; Fagnoni, P; Guiu, B; Hillon, P; Sautou, V; Tavernier, J; Vadot, L | 1 |
| Boulin, M; Cercueil, JP; Delhom, E; Denys, A; Fohlen, A; Guiu, B; Herrero, A; Imbs, DC; Panaro, F; Schmitt, A; Wendremaire, M | 1 |
| El-Kawy, OA; Talaat, HM | 1 |
| Baj, G; Dapas, B; Farra, R; Grassi, G; Grassi, M; Pozzato, G; Scaggiante, B; Zanconati, F | 1 |
| Anota, A; Bedenne, L; Bonnetain, F; Boulin, M; Cercueil, JP; Dabakuyo-Yonli, S; Guiu, B; Hillon, P; Jouve, JL; Minello, A; Paoletti, X | 1 |
| Boulin, M; Cercueil, JP; Chauffert, B; Cherblanc, V; Favelier, S; Guiu, B; Hamza, S; Hillon, P; Krausé, D; Lepage, C | 1 |
1 review(s) available for idarubicin and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Liver chemoembolization of hepatocellular carcinoma using TANDEM
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Doxorubicin; Drug Carriers; Drug Liberation; Humans; Idarubicin; Liver; Liver Neoplasms; Microspheres; Particle Size; Randomized Controlled Trials as Topic; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
6 trial(s) available for idarubicin and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Study protocol for locoregional precision treatment of hepatocellular carcinoma with transarterial chemoembolisation (TACTida), a clinical study: idarubicin dose selection, tissue response and survival.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Idarubicin; Liver Neoplasms; Treatment Outcome | 2022 |
Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: The LIDA-B phase I trial.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Emulsions; Ethiodized Oil; Female; Humans; Idarubicin; Injections, Intra-Arterial; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Quality of Life; Safety; Treatment Outcome | 2018 |
Idarubicin-loaded Beads for Chemoembolization of Hepatocellular Carcinoma: The IDASPHERE II Single-Arm Phase II Trial.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Idarubicin; Liver Neoplasms; Male; Middle Aged | 2019 |
Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Quality of Life; Survival Rate; Treatment Outcome | 2014 |
Clinical and economic impact of drug eluting beads in transarterial chemoembolization for hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cost-Benefit Analysis; Doxorubicin; Drug Carriers; Drug Costs; Ethiodized Oil; Female; Humans; Idarubicin; Liver Neoplasms; Male; Microspheres; Middle Aged; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
An explorative study to assess the association between health-related quality of life and the recommended phase II dose in a phase I trial: idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease-Free Survival; Fatigue; Female; Humans; Idarubicin; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Pain; Quality of Life | 2016 |
16 other study(ies) available for idarubicin and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Stability of a high-concentrated aqueous solution of idarubicin stored in a polypropylene syringe for transarterial chemoembolization.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Drug Stability; Humans; Idarubicin; Liver Neoplasms; Polypropylenes; Syringes | 2022 |
Idarubicin-Loaded DEB-TACE plus Lenvatinib versus Lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score-matching analysis.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Idarubicin; Liver Neoplasms; Propensity Score; Retrospective Studies | 2023 |
Idarubicin-loaded biodegradable microspheres enhance sensitivity to anti-PD1 immunotherapy in transcatheter arterial chemoembolization of hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Chemoembolization, Therapeutic; Emulsions; Idarubicin; Immunotherapy; Liver Neoplasms; Mice; Mice, Inbred C57BL; Microspheres; Rabbits; Treatment Outcome; Tumor Microenvironment | 2023 |
Idarubicin versus epirubicin in drug-eluting beads-transarterial chemoembolization for treating hepatocellular carcinoma: A real-world retrospective study.
Topics: Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Epirubicin; Humans; Idarubicin; Liver Neoplasms; Retrospective Studies; Treatment Outcome | 2023 |
Idarubicin
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Doxorubicin; Female; Humans; Idarubicin; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Progression-Free Survival; Retrospective Studies; Treatment Outcome | 2020 |
Is Idarubicin the Future of TACE?
Topics: Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Idarubicin; Liver Neoplasms | 2019 |
Intra-arterial idarubicin_lipiodol without embolization can provide prolonged complete response in hepatocellular carcinoma: A case report.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Ethiodized Oil; Humans; Idarubicin; Infusions, Intra-Arterial; Liver Neoplasms; Male; Treatment Outcome | 2020 |
Predictive factors of transarterial chemoembolisation toxicity in unresectable hepatocellular carcinoma.
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Aspartate Aminotransferases; Carcinoma, Hepatocellular; Chemical and Drug Induced Liver Injury; Chemoembolization, Therapeutic; Cohort Studies; Doxorubicin; Female; Hepatic Encephalopathy; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Idarubicin; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Liver Failure, Acute; Liver Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Risk Factors; Treatment Outcome; Tumor Burden | 2014 |
Editorial: IDASPHERE phase I trial for chemoembolisation of HCC.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Idarubicin; Liver Neoplasms; Male | 2014 |
Editorial: IDASPHERE phase I trial for chemoembolisation for HCC - authors' reply: a necessary step for treatment optimisation and standardisation.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Idarubicin; Liver Neoplasms; Male | 2014 |
Idarubicin-loaded ONCOZENE drug-eluting embolic agents for chemoembolization of hepatocellular carcinoma: in vitro loading and release and in vivo pharmacokinetics.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Delayed-Action Preparations; Diffusion; Hemostatics; Humans; Idarubicin; Liver Neoplasms; Male; Metabolic Clearance Rate; Polymethacrylic Acids; Treatment Outcome | 2015 |
Comparison of two transarterial chemoembolization strategies for hepatocellular carcinoma.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Epirubicin; Ethiodized Oil; Female; Humans; Idarubicin; Infusions, Intra-Arterial; Liver Neoplasms; Male; Retrospective Studies; Treatment Outcome | 2014 |
Improved stability of lipiodol-drug emulsion for transarterial chemoembolisation of hepatocellular carcinoma results in improved pharmacokinetic profile: Proof of concept using idarubicin.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Ethiodized Oil; Female; Humans; Idarubicin; Liver Neoplasms; Male; Prospective Studies; Treatment Outcome | 2016 |
Preparation, characterization and evaluation of (186) Re-idarubicin: a novel agent for diagnosis and treatment of hepatocellular carcinoma.
Topics: Animals; Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA Topoisomerases, Type II; Humans; Idarubicin; Liver Neoplasms; Mice; Molecular Docking Simulation; Protein Binding; Radioisotopes; Radiopharmaceuticals; Rhenium; Tissue Distribution; Topoisomerase II Inhibitors | 2016 |
Aptamer targeting of the elongation factor 1A impairs hepatocarcinoma cells viability and potentiates bortezomib and idarubicin effects.
Topics: Antineoplastic Agents; Apoptosis; Aptamers, Nucleotide; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Delivery Systems; Hep G2 Cells; Humans; Idarubicin; Liposomes; Liver Neoplasms; Microscopy, Confocal; Microscopy, Fluorescence; Peptide Elongation Factor 1; Time Factors | 2016 |
Lipiodol trans-arterial chemoembolization of hepatocellular carcinoma with idarubicin: first experience.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cohort Studies; Confidence Intervals; Disease-Free Survival; Ethiodized Oil; Female; Femoral Artery; Follow-Up Studies; Humans; Idarubicin; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prospective Studies; Risk Assessment; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2013 |